Form 4: Alnylam CCO's Equity Transactions: RSU Grant & Tax Sales

Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, reported the grant of restricted stock units and stock options, alongside sales of common stock to cover tax obligations.

Summary

• Tolga Tanguler, EVP, Chief Commercial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), reported transactions on March 2, 2026.
• Acquired 4,769 shares of Common Stock through Restricted Stock Units (RSUs) at a price of $0.0 per share.
• Acquired 10,480 Stock Options (right to buy) with an exercise price of $325.07 per share.
• Disposed of a total of 1,608 shares of Common Stock through multiple transactions.
• These dispositions were automatic 'sell-to-cover' sales by the company to satisfy minimum statutory tax withholding obligations related to equity awards.
• The sales occurred at weighted average prices ranging from $323.62 to $332.64 per share.
• Following these transactions, the reporting person directly owns 36,606 shares of Common Stock and 10,480 derivative Stock Options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. The grant of new equity awards to a key executive is a positive sign of continued incentive and alignment, while the sales are routine for tax purposes and do not necessarily indicate a negative sentiment towards the company's future.

Positives

• The grant of 4,769 Restricted Stock Units (RSUs) and 10,480 Stock Options indicates continued equity-based compensation and alignment of management's interests with shareholders.
• The RSUs vest over a three-year period, and stock options vest over four years, subject to continuous service, providing long-term incentive for the Chief Commercial Officer.

Negatives

• The sale of 1,608 shares of common stock, even if for tax purposes, represents a reduction in the reporting person's direct equity holdings.

Future Outlook

The filing details future vesting schedules for the granted equity awards. Restricted Stock Units will vest one-third annually over three years, and stock options will vest 25% on the first anniversary, with remaining shares vesting quarterly until the fourth anniversary, all contingent on continuous service.

Industry Context

StockSavvy.ai notes that routine insider transaction filings, such as Form 4s, are common in the biotechnology and pharmaceutical sectors. Equity compensation, including RSUs and stock options, is a standard practice to attract and retain executive talent in this highly competitive industry. Sell-to-cover transactions for tax obligations are also a typical occurrence and generally do not signal a change in management's long-term outlook on the company.

Comparison to Industry Standards

• This Form 4 filing primarily details insider equity transactions and does not contain company-specific financial or operational data that would allow for a direct comparison to industry-wide performance benchmarks or specific competitor results.

Stakeholder Impact

• Shareholders: The grant of new equity awards could lead to minor future dilution but also aligns executive incentives with shareholder value creation. The 'sell-to-cover' sales are a routine part of equity compensation and are unlikely to significantly impact shareholder sentiment.
• Employees: The equity grants demonstrate the company's compensation strategy for key executives, which can influence overall employee compensation practices and morale.

Next Steps

• RSUs will vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the March 2, 2026 grant date.
• Stock options will vest 25% on the first anniversary of the March 2, 2026 grant date, with the remaining shares vesting in equal installments quarterly until the fourth anniversary.

Key Dates

Recommendation

This Form 4 filing details routine insider equity compensation and tax-related sales. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are typical for an executive receiving equity awards, suggesting a 'hold' recommendation as there's no strong signal for either buying or selling based solely on this filing.

Keywords

Alnylam Pharmaceuticals, ALNY, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Equity Compensation, Chief Commercial Officer, Tolga Tanguler